Market Overview

Recap: Myriad Genetics Q4 Earnings


Shares of Myriad Genetics (NASDAQ:MYGN) moved higher by 1.64% in after-market trading after the company reported Q4 results.

Quarterly Results

Earnings per share fell 175.61% year over year to ($0.31), which beat the estimate of ($0.47).

Revenue of $93,200,000 declined by 56.73% year over year, which missed the estimate of $93,850,000.


Myriad Genetics hasn't issued any earnings guidance for the time being.

Myriad Genetics hasn't issued any revenue guidance for the time being.

Conference Call Details

Date: Aug 13, 2020

Time: 04:30 PM

ET Webcast URL:

Recent Stock Performance

52-week high: $47.10

Company's 52-week low was at $9.24

Price action over last quarter: down 5.97%

Company Profile

Myriad Genetics is a molecular diagnostics company, which provides testing services designed to assess an individual's risk of developing a disease. The firm produces myRisk, a 28-gene panel with the capability to identify the elevated risk of developing 8 types of cancer. Other diagnostic products include BRACAnalysisCDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; Vectra DA, which predicts disease progression in rheumatoid arthritis to optimize drug treatment; and Prolaris, which identifies prostate cancer patients that can pursue active surveillance. The firm also offers biomarker discovery and companion diagnostic services to pharmaceutical and biotechnology companies.


Related Articles (MYGN)

View Comments and Join the Discussion!

Posted-In: Earnings